万邦医药 (301520.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	233.7M	274.2M	379.1M	341.8M	260.8M
Cost of Revenue	180.5M	203.2M	229.1M	174.5M	129.4M
Gross Profit	53.2M	71.0M	150.0M	167.3M	131.4M
Operating Expenses
R&D Expense	30.2M	32.9M	60.7M	34.5M	16.0M
SG&A Expense	—	—	—	—	—
General & Admin Expense	21.5M	22.6M	26.9M	20.7M	12.5M
Selling & Marketing Expense	5.7M	5.8M	4.9M	4.5M	4.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	58.3M	62.0M	90.9M	56.3M	32.8M
Cost and Expenses	238.8M	265.1M	319.9M	230.8M	162.2M
Operating Income (EBIT)	27.9M	41.5M	87.0M	119.0M	106.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	22.3M	35.9M	89.5M	119.6M	111.1M
Income Tax Expense	(2.0M)	(581.3K)	4.0M	11.6M	12.4M
Bottom Line
Net Income	24.3M	36.4M	85.5M	108.1M	98.7M
Earnings from Cont. Ops	24.3M	36.4M	85.5M	108.1M	98.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	24.3M	36.4M	85.5M	108.1M	98.7M
Per Share
Basic EPS	CN¥0.36	CN¥0.55	CN¥1.28	CN¥2.00	CN¥1.97
Diluted EPS	CN¥0.36	CN¥0.55	CN¥1.28	CN¥2.00	CN¥1.97
Revenue Per Share	CN¥3.48	CN¥4.14	CN¥5.67	CN¥6.32	CN¥5.20
Shares
Basic Shares Outstanding	67.1M	66.2M	66.8M	54.0M	50.1M
Diluted Shares Outstanding	67.1M	66.2M	66.8M	54.0M	50.1M
Profitability Metrics
EBITDA	—	61.3M	106.0M	131.4M	113.3M
D&A	—	19.8M	19.0M	12.3M	7.2M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026